REACT: a randomized trial to assess the efficacy and safety of clazosentan for preventing clinical deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage

Clazosentan administered for up to 14 days at 15 mg/hour had no significant effect on the occurrence of clinical deterioration due to DCI. Clinical trial registration no.: NCT03585270 (ClinicalTrials.gov) EU clinical trial registration no.: 2018-000241-39 (clinicaltrialsregister.eu).

Authors

Institutions

Publication Details

Journal
Journal of neurosurgery
Published
2024-08-01
DOI
https://doi.org/10.3171/2024.4.jns232191
Citations
20
Primary Topic
Intracranial Aneurysms: Treatment and Complications
Type
article
Field-Weighted Citation Impact
7.38

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

REACT: a randomized trial to assess the efficacy and safety of clazosentan for preventing clinical deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage

Anthony M. Kaufmann, Stephan A. Mayer, Peter Birkeland, Nicholas C. Bambakidis et al.
20 citations
Journal of neurosurgery
Intracranial Aneurysms: Treatment and Complications
7.38
article

REACT: a randomized trial to assess the efficacy and safety of clazosentan for preventing clinical deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage

Anthony M. Kaufmann, Stephan A. Mayer, Peter Birkeland, Nicholas C. Bambakidis, Thanh N. Nguyen, S. Szabó, Hazem Shoirah, Maciej Śniegocki, Andreas Unterberg, J.F. Alén, François Aldrich, Marina Munari, Antti Ronkainen, John Reavey‐Cantwell, S Rehák, Kevin M. Cockroft, Alfonso Lagares, Dariusz J. Jaskólski, Vincent Costalat, Sylvia Bele, Philippe Séguin, Vincent Legros, Gwynedd E. Pickett, E. François Aldrich, Justiina Huhtakangas, Moshe Attia, Johan Ljungqvist, Ajith J. Thomas, Jacques Créteur, Gregory J. Zipfel, Sagi Harnof, Ramón Torné, Russell Chabanne, András Büki, Lionel Calviere, Angelina Marr, Eric A. Sauvageau, Ansgar Berlis, Pierre Simeone, Maria Wostrack, Martin Smrčka, Attila Lajgut, Philipp Dammann, Fabián Romero-Chala, Jesse Liu, Angelika Ehlert, Masoom Desai, Oscar Åneman, Ola Nilsson, Sébastiên Roux, Sandra Rossi, Anselmo Caricato, Robert Juszkat, J Mocco, Manfred Westphal, Vincent Degos, Étienne Gayat, Ciarán J. Powers, Sepideh Amin‐Hanjani, Xavier Wittebole, Vladimír Přibáň, Nils Hecht, Florian Geßler, Paweł Słoniewski, Thomas Ritzenthaler, Luc Defreyne, Jan Leppert, Péter Tóth, Henry Hyunshik Woo, Claudius Thomé, Tim E. Darsaut, Michael T. Froehler, Pál Barzó, Jaakko Rinne, Przemysław Kunert, Anne‐Claire Lukaszewicz, Juergen Konczalla, Bappaditya Ray, J. van Loon, Ondřej Bradáč, Troels Halfeld Nielsen, Ilker Y. Eyüpoglu, Giuseppe Citerio, Randall T. Higashida, Johanna Eneling, Bertrand Rozec, Thanh Nguyen, Martin Sameš, Paul Singh, Andreas Gruber, Javier Ibáñez, William R. Freeman, Stefan Wolf, Christopher S. Ogilvy, Sebastian Brandner, J. Marc Simard, Andreu Gabarrós Canals, Kadir Erkmen, Gary Steinberg, Ralph König, Rajiv Gupta, Didier Ledoux, A. Petridis, Jia Romit, Yigal Shoshann, Leon Levi, Michael Kelly, Jacqueline Oliveira Garcia, Carlos Dominguez Alonso, J.C. Dumont, Jan Claassen, Cécile Dubois, Ahmed Cheema, Ali Alaraj, Timo Koivisto, Nicolas Bruder, Jan F. Cornelius, Fuat Arikan Abello, Jesús Morera Molina, Karl J. Friston
article en
20 citations

Abstract

Clazosentan administered for up to 14 days at 15 mg/hour had no significant effect on the occurrence of clinical deterioration due to DCI. Clinical trial registration no.: NCT03585270 (ClinicalTrials.gov) EU clinical trial registration no.: 2018-000241-39 (clinicaltrialsregister.eu).

Journal of neurosurgeryVol. 142(1)
Boston University (US), University of Maryland, Baltimore (US), Boston Medical Center (US), Westchester Medical Center (US), New York Medical College (US), Aix-Marseille Université (FR), Ghent University Hospital (BE), Health Net (US), Massachusetts General Hospital (US), University Hospital Brno (CZ), University of California San Francisco Medical Center (US), Hospital Clínic de Barcelona (ES), Idorsia (Switzerland) (CH), University of Milano-Bicocca (IT), Zimmer Biomet (Switzerland) (CH)
Idorsia Pharmaceuticals
Good health and well-being
Openalex Percentile: Top 2%
Intracranial Aneurysms: Treatment and Complications
7.38
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.